Published in Diabetes on June 01, 2004
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes (2009) 2.51
In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? Diabetes Care (2008) 1.52
Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care (2009) 1.48
The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab (2008) 1.37
Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care (2010) 1.33
Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics (2010) 1.24
From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care (2010) 1.21
Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. CMAJ (2009) 1.19
Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity. Cardiovasc Diabetol (2007) 1.11
Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes (2012) 1.10
Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes? Am J Physiol Endocrinol Metab (2008) 0.98
Hemoglobin A1c above threshold level is associated with decreased β-cell function in overweight Latino youth. J Pediatr (2011) 0.91
Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes. PLoS One (2016) 0.90
Determinants of impaired fasting glucose versus glucose intolerance in polycystic ovary syndrome. Diabetes Care (2010) 0.87
Impact of ADMA, endothelial progenitor cells and traditional cardiovascular risk factors on pulse wave velocity among prediabetic individuals. Cardiovasc Diabetol (2012) 0.85
Relation of low glomerular filtration rate to metabolic disorders in individuals without diabetes and with normoalbuminuria. Clin J Am Soc Nephrol (2008) 0.85
Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care (2013) 0.85
Development of coronary heart disease and ischemic stroke in relation to fasting and 2-hour plasma glucose levels in the normal range. Cardiovasc Diabetol (2012) 0.83
Consistency of the disposition index in the face of diet induced insulin resistance: potential role of FFA. PLoS One (2011) 0.80
Linking pre-diabetes with benign prostate hyperplasia. IGFBP-3: a conductor of benign prostate hyperplasia development orchestra? PLoS One (2013) 0.79
Moderate diet-induced weight loss is associated with improved insulin sensitivity in middle-aged healthy obese Korean women. Nutr Res Pract (2014) 0.79
Fasting but not postprandial (postmeal) glycemia predicts the risk of death in subjects with coronary artery disease. Can J Cardiol (2007) 0.78
Relationship and factors responsible for regulating fasting and post-challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus. J Diabetes Investig (2014) 0.78
Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action. J Viral Hepat (2011) 0.77
Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance. J Diabetes Res (2015) 0.76
Correlation between mean platelet volume and blood glucose levels after oral glucose loading in normoglycemic and prediabetic Japanese subjects. J Diabetes Investig (2013) 0.76
Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans. J Clin Endocrinol Metab (2016) 0.75
Oral glucose tolerance test-based calculation identifies different glucose intolerance phenotypes within the impaired fasting glucose range. J Diabetes Investig (2014) 0.75
Metabolic syndrome and the early detection of impaired glucose tolerance among professionals living in Beijing, China: a cross sectional study. Diabetol Metab Syndr (2013) 0.75
Strong association between insulin-mediated glucose uptake and the 2-hour, not the fasting plasma glucose concentration, in the normal glucose tolerance range. J Clin Endocrinol Metab (2014) 0.75
A Unifying Organ Model of Pancreatic Insulin Secretion. PLoS One (2015) 0.75
Associations of lipid profiles with insulin resistance and β cell function in adults with normal glucose tolerance and different categories of impaired glucose regulation. PLoS One (2017) 0.75
Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol (2002) 35.63
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr (2004) 9.01
The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med (2003) 7.94
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17
The prevention and treatment of missing data in clinical trials. N Engl J Med (2012) 6.92
Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation (2005) 6.80
The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53
Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes (2006) 6.52
Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging (2005) 5.84
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA (2009) 5.75
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care (2003) 5.27
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 5.11
Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med (2002) 5.10
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 4.58
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet (2010) 4.53
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med (2008) 3.99
Socioeconomic position and health among persons with diabetes mellitus: a conceptual framework and review of the literature. Epidemiol Rev (2004) 3.74
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care (2006) 3.67
Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med (2003) 3.54
Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care (2004) 3.51
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care (2005) 3.09
LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis (2007) 3.08
Social disparities in internet patient portal use in diabetes: evidence that the digital divide extends beyond access. J Am Med Inform Assoc (2011) 3.07
C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab (2003) 3.04
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
The literacy divide: health literacy and the use of an internet-based patient portal in an integrated health system-results from the diabetes study of northern California (DISTANCE). J Health Commun (2010) 2.97
Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology (2006) 2.95
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care (2002) 2.92
Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes (2003) 2.76
Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol (2005) 2.75
Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation (2005) 2.63
Cohort Profile: The Diabetes Study of Northern California (DISTANCE)--objectives and design of a survey follow-up study of social health disparities in a managed care population. Int J Epidemiol (2008) 2.59
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care (2005) 2.53
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes (2009) 2.51
Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol (2003) 2.51
Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care (2010) 2.51
C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes (2008) 2.50
Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation (2005) 2.46
Communication and medication refill adherence: the Diabetes Study of Northern California. JAMA Intern Med (2013) 2.44
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes (2005) 2.42
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42
The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes (2006) 2.40
Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation (2003) 2.32
Does literacy mediate the relationship between education and health outcomes? A study of a low-income population with diabetes. Public Health Rep (2006) 2.30
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? Circulation (2010) 2.25
Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes (2003) 2.22
One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics (2007) 2.20
Case-control single-marker and haplotypic association analysis of pedigree data. Genet Epidemiol (2005) 2.19
Urine albumin excretion and subclinical cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis. Hypertension (2005) 2.18
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care (2002) 2.16
Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol (2003) 2.12
Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care (2008) 2.12
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09
Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation (2005) 2.08
Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2004) 2.08
Sleep duration as a risk factor for incident type 2 diabetes in a multiethnic cohort. Ann Epidemiol (2009) 2.07
Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care (2011) 2.04
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet (2012) 2.02
Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev (2007) 1.98
Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol (2006) 1.98
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J (2006) 1.98
Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA (2010) 1.97
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood (2008) 1.97
Risk factors for mortality among patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care (2007) 1.95
Race/ethnicity and economic differences in cost-related medication underuse among insured adults with diabetes: the Translating Research Into Action for Diabetes Study. Diabetes Care (2007) 1.95
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.91
Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. Arch Intern Med (2005) 1.91
Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke (2002) 1.90
Dyslipidemia management in adults with diabetes. Diabetes Care (2004) 1.89